1. Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations.
- Author
-
Abou-Foul AK, Henson C, Chernock RD, Huang SH, Lydiatt WM, McDowell L, O'Sullivan B, Perez-Ordonez B, Robinson M, Nankivell PC, Ruiz-Bravo E, Chiosea SI, Green TM, Hunter KD, Hwang JS, Koljenovic S, Koppes SA, Larsen SR, Lo AWI, Costes-Martineau V, Mittal N, Mori T, Nagao T, Panayiotides IG, Pinto CAL, Scheckenbach K, Seethala RR, Ulhøi BP, Vingiani A, Zhang Y, Yom SS, and Mehanna H
- Subjects
- Humans, Squamous Cell Carcinoma of Head and Neck pathology, Terminology as Topic, Head and Neck Neoplasms pathology, Consensus, Delphi Technique, Extranodal Extension pathology
- Abstract
Detection of extranodal extension on histopathology in surgically treated head and neck squamous cell carcinoma indicates poor prognosis. However, there is no consensus on the diagnostic criteria, interpretation, and reporting of histology detected extranodal extension, which has contributed to conflicting evidence in the literature, and likely clinical inconsistency. The Head and Neck Cancer International Group conducted a three-round modified Delphi process with a group of 19 international pathology experts representing 15 national clinical research groups to generate consensus recommendations for histology detected extranodal extension diagnostic criteria. The expert panel strongly agreed on terminology and diagnostic features for histology detected extranodal extension and soft tissue metastasis. Moreover, the panel reached consensus on reporting of histology detected extranodal extension and on nodal sampling. These consensus recommendations, endorsed by 19 organisations representing 34 countries, are a crucial development towards standardised diagnosis and reporting of histology detected extranodal extension, and more accurate data collection and analysis., Competing Interests: Declaration of interests HM is the Director and a shareholder of Warwickshire Head and Neck Clinic; chair of the Head and Neck Cancer International Group; past president of the British Association of Head and Neck Oncologists; reports receiving honoraria from AstraZeneca; is on the Speaker's Bureau for Merck Sharpe Dohme (MSD), Sanofi Pasteur, and Merck; received funding from GSK Biologicals, MSD, Sanofi Pasteur, GSK, and AstraZeneca; and received travel accommodation expenses from Sanofi Pasteur, MSD, and Merck. WML is the chair of American Joint Committee on Cancer 9th Version head and neck task force. RDC is a member of a steering committee for a phase 3 clinical trial of neoadjuvant pembrolizumab sponsored by Merck and also has a non-financial relationship with Caris Life Sciences as a member of their Precision Oncology Alliance. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF